Tamoxifen only works if your body can activate it. A single DNA test reveals whether yours can — and guides better treatment decisions.
June 2026 · 9 min read · Lambert Medical Clinical Team
Tamoxifen has been a cornerstone of breast cancer treatment for decades. It is prescribed to hundreds of thousands of women with oestrogen receptor-positive (ER+) breast cancer — the most common type, accounting for approximately 80% of all cases. Yet despite its long track record, there is a fundamental fact about tamoxifen that many patients, and even some clinicians, are not fully aware of: tamoxifen itself has almost no anti-cancer activity.
Like codeine, tamoxifen is a prodrug — a pharmacologically inactive compound that must be converted by the liver into its active form to exert its therapeutic effect. The conversion happens through a complex metabolic pathway involving several liver enzymes, but the critical step — the one that determines whether tamoxifen will actually work — is performed by a single enzyme: CYP2D6.
CYP2D6 converts tamoxifen into endoxifen, its primary active metabolite. Endoxifen is the compound responsible for tamoxifen's anti-oestrogenic effects — blocking oestrogen receptors on cancer cells and suppressing tumour growth. Crucially, endoxifen is up to 100 times more potent as an antioestrogen than tamoxifen itself.
Women who cannot efficiently convert tamoxifen to endoxifen — because of their inherited CYP2D6 genetics — may be taking a drug that provides substantially less protection than expected. Meanwhile, they experience the same side effects as women with full CYP2D6 activity. This is not a rare edge case: poor and intermediate metabolisers together represent approximately 15–20% of the population.
The relationship between CYP2D6 genotype and tamoxifen outcomes has been extensively studied. A comprehensive 2025 review published in the Journal of Personalized Medicine (Saad et al.) examined the full body of evidence on genetic and drug–drug interactions affecting tamoxifen metabolism. Key findings include:
One of the most clinically important — and underappreciated — risks involves the antidepressants commonly prescribed alongside tamoxifen. Hot flushes are a major side effect of tamoxifen therapy, and SSRIs are frequently prescribed to manage them. The problem: several of the most commonly prescribed SSRIs are potent CYP2D6 inhibitors.
| Antidepressant | CYP2D6 Inhibition | Impact on Endoxifen | Alternative? |
|---|---|---|---|
| Paroxetine (Seroxat) | Strong | Major reduction | Yes — venlafaxine or citalopram preferred |
| Fluoxetine (Prozac) | Strong | Major reduction | Yes — avoid during tamoxifen |
| Bupropion | Moderate–strong | Significant reduction | Yes — consider alternatives |
| Duloxetine | Moderate | Moderate reduction | Monitor or switch |
| Venlafaxine | Minimal | Minimal impact | Preferred option for hot flushes |
| Citalopram / Escitalopram | Minimal | Minimal impact | Acceptable with tamoxifen |
A woman who is a normal CYP2D6 metaboliser but taking paroxetine alongside tamoxifen may be functionally converted into a poor metaboliser — receiving all the side effects of tamoxifen with a fraction of the benefit. This drug–gene interaction is clinically actionable and entirely preventable with a PGx test before prescribing decisions are made.
The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published explicit pharmacogenomics guidelines for tamoxifen. Their recommendations, based on CYP2D6 phenotype, are:
Consider alternative endocrine therapy (aromatase inhibitor in post-menopausal women) or higher tamoxifen dose (40 mg/day) under specialist supervision. Avoid CYP2D6 inhibitor co-medications.
Consider dose increase or alternative. Monitor endoxifen levels where possible. Avoid strong CYP2D6 inhibitors.
Standard tamoxifen appropriate. Avoid co-prescription of paroxetine or fluoxetine for hot flush management — use venlafaxine or citalopram instead.
Standard tamoxifen appropriate. Higher endoxifen levels may be associated with stronger anti-oestrogenic effects; monitor for side effects. Data on clinical outcomes is more limited.
Despite compelling evidence and clear clinical guidelines, CYP2D6 testing before tamoxifen is not yet routinely performed in NHS oncology. Clinical evidence exists, guidance is published, but commissioning has not caught up. The result is that the majority of women starting tamoxifen in the UK have no idea whether their body can actually activate the drug they have been prescribed to protect their life.
Private testing changes this. A pharmacogenomics cheek swab at Lambert Medical Practice costs £299, provides results in 10–14 working days, and is valid for life. The test report is shareable with your oncologist, breast surgeon, or GP — it becomes a permanent part of your prescribing record.
Our full PGx panel covers tamoxifen metabolism (CYP2D6), co-medication interactions including SSRIs, pain medications, cardiovascular drugs, and 50+ additional clinically actionable medications. Simple cheek swab. Results in 10–14 working days. GP interpretation included.
Know your CYP2D6 type before starting tamoxifen. One cheek swab. GP interpretation. Lifetime valid.
Book PGx Test Full details